PT910406E - Herpesvírus caninos recombinantes - Google Patents

Herpesvírus caninos recombinantes Download PDF

Info

Publication number
PT910406E
PT910406E PT97915994T PT97915994T PT910406E PT 910406 E PT910406 E PT 910406E PT 97915994 T PT97915994 T PT 97915994T PT 97915994 T PT97915994 T PT 97915994T PT 910406 E PT910406 E PT 910406E
Authority
PT
Portugal
Prior art keywords
seq
chv
nucleic acid
gene
acid molecule
Prior art date
Application number
PT97915994T
Other languages
English (en)
Portuguese (pt)
Inventor
Elizabeth J Haanes
Rexann A Frank
Original Assignee
Merial Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merial Ltd filed Critical Merial Ltd
Publication of PT910406E publication Critical patent/PT910406E/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A61P31/22—Antivirals for DNA viruses for herpes viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/10—Transferases (2.)
    • C12N9/12—Transferases (2.) transferring phosphorus containing groups, e.g. kinases (2.7)
    • C12N9/1205—Phosphotransferases with an alcohol group as acceptor (2.7.1), e.g. protein kinases
    • C12N9/1211—Thymidine kinase (2.7.1.21)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/16011—Herpesviridae
    • C12N2710/16711—Varicellovirus, e.g. human herpesvirus 3, Varicella Zoster, pseudorabies
    • C12N2710/16721—Viruses as such, e.g. new isolates, mutants or their genomic sequences
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/16011—Herpesviridae
    • C12N2710/16711—Varicellovirus, e.g. human herpesvirus 3, Varicella Zoster, pseudorabies
    • C12N2710/16722—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/16011—Herpesviridae
    • C12N2710/16711—Varicellovirus, e.g. human herpesvirus 3, Varicella Zoster, pseudorabies
    • C12N2710/16741—Use of virus, viral particle or viral elements as a vector
    • C12N2710/16743—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Zoology (AREA)
  • Biotechnology (AREA)
  • Virology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Microbiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Biophysics (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Plant Pathology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Physics & Mathematics (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
PT97915994T 1996-02-15 1997-02-14 Herpesvírus caninos recombinantes PT910406E (pt)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US08/602,010 US5753235A (en) 1996-02-15 1996-02-15 Recombinant canine herpesviruses

Publications (1)

Publication Number Publication Date
PT910406E true PT910406E (pt) 2007-03-30

Family

ID=24409615

Family Applications (1)

Application Number Title Priority Date Filing Date
PT97915994T PT910406E (pt) 1996-02-15 1997-02-14 Herpesvírus caninos recombinantes

Country Status (12)

Country Link
US (5) US5753235A (https=)
EP (1) EP0910406B1 (https=)
JP (1) JP2000505297A (https=)
AT (1) ATE347375T1 (https=)
AU (1) AU728676B2 (https=)
CA (1) CA2243662A1 (https=)
DE (1) DE69737058T2 (https=)
DK (1) DK0910406T3 (https=)
ES (1) ES2281098T3 (https=)
NZ (1) NZ331079A (https=)
PT (1) PT910406E (https=)
WO (1) WO1997029772A1 (https=)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5753235A (en) * 1996-02-15 1998-05-19 Heska Corporation Recombinant canine herpesviruses
FR2750865B1 (fr) * 1996-06-27 1998-12-04 Rhone Merieux Vaccin vivant recombinant a base d'herpesvirus canin, notamment contre la maladie de carre, la rage ou le virus parainfluenza de type 2
AU728581B2 (en) * 1996-09-13 2001-01-11 Lipoxen Limited Liposomes
CA2245408A1 (en) * 1997-08-21 1999-02-21 York University High-throughput screens for enzyme inhibitors
CN1263854C (zh) 1997-11-06 2006-07-12 启龙股份公司 奈瑟球菌抗原
AU1979599A (en) 1998-01-14 1999-08-02 Chiron S.P.A. (neisseria meningitidis) antigens
EP2261352A3 (en) 1998-05-01 2012-01-04 Novartis Vaccines and Diagnostics, Inc. Neisseria meningitidis antigens and compositions
JP2003518363A (ja) 1999-04-30 2003-06-10 カイロン エセ．ピー．アー． 保存されたナイセリア抗原
PT2289545T (pt) 2000-01-17 2016-09-06 Glaxosmithkline Biologicals Sa Vacina de omv suplementada contra meningococos
US6551598B2 (en) * 2000-01-21 2003-04-22 Merial Vaccination against canine herpesvirosis and vaccines therefor
FR2804026B1 (fr) * 2000-01-21 2004-06-11 Merial Sas Vaccination contre l'herpesvirose canine et vaccins
DK1328543T3 (da) 2000-10-27 2009-11-23 Novartis Vaccines & Diagnostic Nukleinsyrer og proteiner fra streptococcus-gruppe A & B
US20030129680A1 (en) * 2001-10-31 2003-07-10 O'connor Thomas Patrick Multi-analyte assay device
EP1390499A2 (en) * 2001-03-02 2004-02-25 Florigene Limited Cell visual characteristic-modifying sequences
GB0107658D0 (en) 2001-03-27 2001-05-16 Chiron Spa Streptococcus pneumoniae
GB0107661D0 (en) 2001-03-27 2001-05-16 Chiron Spa Staphylococcus aureus
AU2002305322B2 (en) 2001-05-03 2008-05-22 Children's Medical Center, Corporation Sperm-specific cation channel, and uses therefor
US8729248B2 (en) * 2001-10-22 2014-05-20 Children's Medical Center Corporation Sperm-specific cation channel, CATSPER2, and uses therefor
CN100515494C (zh) 2001-12-12 2009-07-22 启龙有限公司 抗沙眼衣原体的免疫
US8110668B2 (en) * 2002-08-07 2012-02-07 Children's Medical Center Corporation Sperm-specific cation channel, catsper-3 and uses therefor
AU2003263981A1 (en) * 2002-08-07 2004-02-25 Children's Medical Center Corporation Sperm-specific cation channel, catsper-4, and uses therefor
EP1562982B1 (en) 2002-11-15 2010-05-05 Novartis Vaccines and Diagnostics S.r.l. Unexpected surface proteins in neisseria meningitidis
SE0300795D0 (sv) 2003-03-24 2003-03-24 Isconova Ab Composition comprising iscom particles and live micro-organisms
GB0308198D0 (en) 2003-04-09 2003-05-14 Chiron Srl ADP-ribosylating bacterial toxin
GB0315323D0 (en) * 2003-07-01 2003-08-06 Royal Veterinary College Vaccine composition
US9023366B2 (en) 2003-07-01 2015-05-05 The Royal Veterinary College Vaccine composition for vaccinating dogs against canine infectious respiratory disease (CIRD)
CA2592627C (en) * 2005-01-20 2014-02-25 Isconova Ab Vaccine composition comprising a fibronectin binding protein or a fibronectin binding peptide
EP2333074A1 (en) 2009-12-14 2011-06-15 Robert Steinfeld Substances and methods for the treatment of lysosmal storage diseases

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5223424A (en) * 1985-09-06 1993-06-29 Prutech Research And Development Attenuated herpesviruses and herpesviruses which include foreign DNA encoding an amino acid sequence
US5310668A (en) * 1986-06-20 1994-05-10 Merck & Co., Inc. Varicella-zoster virus as a live recombinant vaccine
US5324664A (en) * 1988-08-08 1994-06-28 The Upjohn Company Herpes virus thymidien kinase-encoding DNA
FR2659349B1 (fr) * 1990-03-12 1993-12-24 Rhone Merieux Virus herpes recombinants notamment pour la realisation de vaccins, leur procede de preparation, les plasmides realises au cours de ce procede et les vaccins obtenus.
ATE369876T1 (de) * 1994-03-30 2007-09-15 Virogenetics Corp Nukleotid- und aminosäuresequenzen gb, gc und gd des herpesvirus des hundes und ihre verwendungen
US5753235A (en) * 1996-02-15 1998-05-19 Heska Corporation Recombinant canine herpesviruses

Also Published As

Publication number Publication date
DE69737058D1 (de) 2007-01-18
EP0910406A4 (en) 2000-01-26
NZ331079A (en) 2000-06-23
EP0910406A1 (en) 1999-04-28
DE69737058T2 (de) 2007-09-06
ES2281098T3 (es) 2007-09-16
US7041813B2 (en) 2006-05-09
CA2243662A1 (en) 1997-08-21
US5804197A (en) 1998-09-08
DK0910406T3 (da) 2007-04-10
JP2000505297A (ja) 2000-05-09
US20060275796A1 (en) 2006-12-07
US5753235A (en) 1998-05-19
EP0910406B1 (en) 2006-12-06
ATE347375T1 (de) 2006-12-15
AU2327897A (en) 1997-09-02
AU728676B2 (en) 2001-01-18
US20030049844A1 (en) 2003-03-13
WO1997029772A1 (en) 1997-08-21
US6159478A (en) 2000-12-12

Similar Documents

Publication Publication Date Title
AU728676B2 (en) Recombinant canine herpesviruses
WO1997029772A9 (en) Recombinant canine herpesviruses
Croizier et al. Extension of Autographa californica nuclear polyhedrosis virus host range by interspecific replacement of a short DNA sequence in the p143 helicase gene.
Ho et al. Herpes simplex virus latent RNA (LAT) is not required for latent infection in the mouse.
DK2467489T3 (en) Baculovirus-based production of biopharmaceuticals free of contaminating baculoviral virions
US6387376B1 (en) Recombinant vaccine containing feline herpes virus type 1 particularly for treating feline infectious peritonitis
TW202146428A (zh) 基於重組痘病毒之抗SARS-CoV-2病毒疫苗
CN112899290B (zh) 一种天然免疫抑制基因缺失的减毒非洲猪瘟病毒株及应用
Schröder et al. From essential to beneficial: glycoprotein D loses importance for replication of bovine herpesvirus 1 in cell culture
White et al. Generation and precise modification of a herpesvirus saimiri bacterial artificial chromosome demonstrates that the terminal repeats are required for both virus production and episomal persistence
CN115605223A (zh) 抗非洲猪瘟病毒感染的疫苗
JP3439472B2 (ja) ヘルペスウイルスチミジンキナーゼをコード付けするｄｎａの単離方法
US5324664A (en) Herpes virus thymidien kinase-encoding DNA
US5292653A (en) Equine herpesvirus 1 tk mutants
JP3710838B2 (ja) ウマヘルペスウイルス感染からウマを防御するためのワクチン
Rösen-WoIff et al. Organotropism of latent herpes simplex virus type 1 is correlated to the presence of a 1.5 kb RNA transcript mapped within the BamHI DNA fragment B (0.738 to 0.809 map units)
OSTERRIEDER et al. The Equine Herpesvirus 1 IR6 Protein Is Nonessential for Virus Growthin Vitroand Modified by Serial Virus Passage in Cell Culture
Smith et al. Nucleotide and amino acid sequence analysis of the thymidine kinase gene of a bovine encephalitis herpesvirus
Jang et al. The genetic organization and transcriptional analysis of the short unique region in the genome of nononcogenic Marek's disease virus serotype 2
Martin et al. Genetic and biochemical characterization of the thymidine kinase gene from herpesvirus of turkeys
Feller et al. Isolation and molecular characterization of the swinepox virus thymidine kinase gene
RU2843901C1 (ru) Вакцина против инфекции вируса африканской чумы свиней
Ortiz et al. Identification of viral membrane proteins required for cell fusion and viral dissemination that are modified during vaccinia virus persistence
US6312696B1 (en) Antigenic protein originating in infectious laryngotracheitis virus
Sommer et al. Bunji Sato, Hideki Ito, Stewart Hinchliffe, Marvin H.